These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 8742781)
1. Drugs that modify opioid tolerance, physical dependence, and abstinence symptoms: preclinical and clinical studies. Bhargava HN NIDA Res Monogr; 1995; 147():53-83. PubMed ID: 8742781 [TBL] [Abstract][Full Text] [Related]
2. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence. Wells JL; Bartlett JL; Ananthan S; Bilsky EJ J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048 [TBL] [Abstract][Full Text] [Related]
3. [Opioid tolerance and dependence--pharmacological aspects]. Jaba IM; Luncanu I; Mungiu OC Rev Med Chir Soc Med Nat Iasi; 2001; 105(3):444-50. PubMed ID: 12092171 [TBL] [Abstract][Full Text] [Related]
4. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling. Wang HY; Friedman E; Olmstead MC; Burns LH Neuroscience; 2005; 135(1):247-61. PubMed ID: 16084657 [TBL] [Abstract][Full Text] [Related]
5. Prevention of morphine discontinuation phenomenon in mice by ondansetron, a selective 5-HT3 antagonist. Roychoudhury M; Kulkarni SK Methods Find Exp Clin Pharmacol; 1996 Dec; 18(10):677-83. PubMed ID: 9121224 [TBL] [Abstract][Full Text] [Related]
6. Structure activity relationship studies with hypothalamic peptide hormones. I. Effect of melanotropin release inhibiting factor and analogs on tolerance to morphine in the rat. Bhargava HN; Kim HS J Pharmacol Exp Ther; 1982 Feb; 220(2):394-8. PubMed ID: 6120229 [TBL] [Abstract][Full Text] [Related]
7. GABA and opioid mechanisms of the central amygdala underlie the withdrawal-potentiated startle from acute morphine. Cabral A; Ruggiero RN; Nobre MJ; Brandão ML; Castilho VM Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):334-44. PubMed ID: 19150477 [TBL] [Abstract][Full Text] [Related]
8. Attenuation of opioid analgesic tolerance in p75 neurotrophin receptor null mutant mice. Trang T; Koblic P; Kawaja M; Jhamandas K Neurosci Lett; 2009 Feb; 451(1):69-73. PubMed ID: 19114089 [TBL] [Abstract][Full Text] [Related]
9. Repetitive opioid abstinence causes progressive hyperalgesia sensitive to N-methyl-D-aspartate receptor blockade in the rat. Dunbar SA; Pulai IJ J Pharmacol Exp Ther; 1998 Feb; 284(2):678-86. PubMed ID: 9454814 [TBL] [Abstract][Full Text] [Related]
10. JNJ-20788560 [9-(8-azabicyclo[3.2.1]oct-3-ylidene)-9H-xanthene-3-carboxylic acid diethylamide], a selective delta opioid receptor agonist, is a potent and efficacious antihyperalgesic agent that does not produce respiratory depression, pharmacologic tolerance, or physical dependence. Codd EE; Carson JR; Colburn RW; Stone DJ; Van Besien CR; Zhang SP; Wade PR; Gallantine EL; Meert TF; Molino L; Pullan S; Razler CM; Dax SL; Flores CM J Pharmacol Exp Ther; 2009 Apr; 329(1):241-51. PubMed ID: 19151246 [TBL] [Abstract][Full Text] [Related]
11. [Opioid analgesics in the treatment of non-malignant chronic pain]. Eriksen J; Clausen TG; Borgbjerg FM Ugeskr Laeger; 1994 Jan; 156(5):621-3, 626-7. PubMed ID: 7910424 [TBL] [Abstract][Full Text] [Related]
12. The opioid mu agonist/delta antagonist DIPP-NH(2)[Psi] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats. Schiller PW; Fundytus ME; Merovitz L; Weltrowska G; Nguyen TM; Lemieux C; Chung NN; Coderre TJ J Med Chem; 1999 Sep; 42(18):3520-6. PubMed ID: 10479285 [TBL] [Abstract][Full Text] [Related]
13. Attenuation of tolerance to opioid-induced antinociception and protection against morphine-induced decrease of neurofilament proteins by idazoxan and other I2-imidazoline ligands. Boronat MA; Olmos G; García-Sevilla JA Br J Pharmacol; 1998 Sep; 125(1):175-85. PubMed ID: 9776358 [TBL] [Abstract][Full Text] [Related]
14. Chronic agonist treatment converts antagonists into inverse agonists at delta-opioid receptors. Liu JG; Prather PL J Pharmacol Exp Ther; 2002 Sep; 302(3):1070-9. PubMed ID: 12183665 [TBL] [Abstract][Full Text] [Related]
15. The substance P amino-terminal metabolite substance P(1-7), administered peripherally, prevents the development of acute morphine tolerance and attenuates the expression of withdrawal in mice. Kreeger JS; Larson AA J Pharmacol Exp Ther; 1996 Nov; 279(2):662-7. PubMed ID: 8930169 [TBL] [Abstract][Full Text] [Related]
16. Opioids: cellular mechanisms of tolerance and physical dependence. Bailey CP; Connor M Curr Opin Pharmacol; 2005 Feb; 5(1):60-8. PubMed ID: 15661627 [TBL] [Abstract][Full Text] [Related]
18. Nuclear factor-kappa-B inhibitor modulates the development of opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome. Rehni AK; Bhateja P; Singh TG; Singh N Behav Pharmacol; 2008 May; 19(3):265-9. PubMed ID: 18469544 [TBL] [Abstract][Full Text] [Related]
19. Diversity of agents that modify opioid tolerance, physical dependence, abstinence syndrome, and self-administrative behavior. Bhargava HN Pharmacol Rev; 1994 Sep; 46(3):293-324. PubMed ID: 7831382 [No Abstract] [Full Text] [Related]
20. Opioid tolerance and dependence in light of the multiplicity of opioid receptors. Schulz R; Herz A NIDA Res Monogr; 1984; 54():70-80. PubMed ID: 6099881 [No Abstract] [Full Text] [Related] [Next] [New Search]